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Long non-coding RNAs (lncRNAs) have been impli-
cated in numerous physiological processes and
diseases, most notably cancers. However, little is
known about the mechanism of many functional
lncRNAs. We identified an abundantly expressed
lncRNA associated with decreased melanoma pa-
tient survival. Increased expression of this lncRNA,
SLNCR1, mediates melanoma invasion through a
highly conserved sequence similar to that of the
lncRNA SRA1. Using a sensitive technique we term
RATA (RNA-associated transcription factor array),
we show that the brain-specific homeobox protein
3a (Brn3a) and the androgen receptor (AR) bind
within and adjacent to SLNCR1’s conserved region,
respectively. SLNCR1, AR, and Brn3a are specifically
required for transcriptional activation of matrix met-
alloproteinase 9 (MMP9) and increased melanoma
invasion. Our observations directly link AR to mela-
noma invasion, possibly explaining why males expe-
rience more melanoma metastases and have an
overall lower survival in comparison to females.INTRODUCTION
The incidence of melanoma worldwide has been on the rise
for the past 30 years. In the United States, it is estimated that
73,870 new cases will be diagnosed, and 9,940 individuals will
die of melanoma in 2015 (Siegel et al., 2015). Most early mela-
nomas are easily treated by surgical excision; once metasta-
sized, melanoma is a highly lethal cancer with a 5-year survival
rate of 16% (Howlader et al., 2015). Thus, prevention of metas-
tasis is key to melanoma survival, and identification of molecular
drivers would enable the development of novel melanoma
therapies.Ce
This is an open access article undThere is mounting evidence that non-coding RNAs are critical
determinants of tumor progression. A major portion (>70,000
genes) of the human non-coding transcriptome comprises long
non-coding RNAs (lncRNAs) (Zhao et al., 2016). Dysregulated
lncRNA expression has recently been linked to many cancers
(Li et al., 2013a). The lncRNAs may act as oncogenes or tumor
suppressors, with an emerging role specifically in cancer metas-
tasis (Serviss et al., 2014). Recent studies implicate lncRNAs in
melanomagenesis, though their exact role in melanoma etiology
is poorly understood because their molecular and biological
functions are obscure (Flockhart et al., 2012; Khaitan et al.,
2011; Tang et al., 2013; Tian et al., 2014; Wu et al., 2013).
We profiled lncRNAs expressed in patient-derivedmelanomas
and identified a lncRNA (XLOC_012568) critical for melanoma in-
vasion. This lncRNA contains a conserved 300-nt region with
significant similarity to steroid receptor RNA activator 1 (SRA1)
and is hence named SLNCR (SRA-like non-coding RNA). Sur-
vival analysis of The Cancer Genome Atlas (TCGA) melanomas
indicates decreased patient survival in patients expressing
high levels of SLNCR. Knockdown of the most prevalent isoform
SLNCR1 results in the differential expression of 111 transcripts
and decreases melanoma invasion. We show that the brain-
specific homeobox protein 3a (Brn3a) and the androgen receptor
(AR) bind to SLNCR1’s conserved sequence and an adjacent
sequence, respectively, and that SLNCR1 coordinates the
transcriptional activities of these transcription factors (TFs) to
upregulate the gene encoding the gelatinase MMP9 and in-
crease melanoma invasion. SLNCR1 binds to and functions
with AR, implicating a hormone-responsive transcription factor
in melanoma invasion. Thus, our results may reconcile the
long-established gender bias in melanoma in which males
have a higher frequency of metastases compared to females.
RESULTS
SLNCR Expression Is Associated with Melanoma
Survival Outcome
To identify melanoma-associated lncRNAs, we performed RNA
sequencing (RNA-seq) on three melanoma short-term culturesll Reports 15, 2025–2037, May 31, 2016 ª 2016 The Authors. 2025
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. SLNCR Is Expressed in Melanomas and Is Associated with Worse Overall Survival
(A) Relative expression of SLNCR across multiple melanocytes and melanomas, as measured by qRT-PCR, compared to A375 after normalization to GAPDH.
(B) Schematic presentation of SLNCR1’s exon structure. The highly conserved and SRA1-like sequences are highlighted.
(C) Boxplot of SLNCR expression from 150 TCGA melanomas categorized based on tumor thickness at diagnosis. Data are represented as mean±SEM.
Significance was calculated using the Student’s t test: *p < 0.05.
(D) Kaplan-Meier survival analysis of high- or low-SLNCR-expressing TCGA melanomas, defined by the median SLNCR expression (RPKM = 14.1).
See also Figure S1.(MSTCs) and fibroblast short-term cultures (FSTCs) derived from
the tumor microenvironment (C.H.Y., unpublished data). MSTCs
have undergone relatively few passages outside of the patient
and closely reflect the genetics of patient melanomas and pro-
vide a tractable system to study disease-relevant transcriptional
changes. Of the 137 lncRNAs expressed in human melanomas
(FPKM [fragments per kilobase per million mapped reads] > 1;
Table S1), the third most abundant lncRNA (XLOC_012568;
linc00673, Refseq NR_036488.1; average FPKM = 55.33) is
expressed in MSTCs but not FSTCs. Moreover, this lncRNA
is located within a chromosomal region commonly amplified
in melanoma, lung, and ovarian cancers (www.broadinstitute.
com/tumorscape; Table S2). We confirmed increased expres-
sion of XLOC_012568 in eight MSTCs compared to three normal
melanocyte controls by qRT-PCR (Figure 1A; Tables S1 and S3).
In addition to melanomas, the MiTranscriptome database (www.
mitranscriptome.org) reveals that XLOC_012568 is increased in
lung adenocarcinoma and squamous cell carcinomas compared
to corresponding normal tissues, while it is decreased in stom-
ach cancers compared to normal tissues (Iyer et al., 2015) (Fig-
ure S1A). XLOC_012568 is also expressed in cervical, ovarian,
and pancreatic cancers; low-grade glioma; and glioblastoma
multiforme. Collectively, these data suggest a broader role for
this lncRNA in human tumorigenesis.
There are three XLOC_012568 isoforms expressed in mela-
nomas (Figure S1B). The most prevalent isoform, SLNCR1, is2026 Cell Reports 15, 2025–2037, May 31, 20162,257 nt and composed of four exons spanning chromosomes
(chr)17:70399463–70588943 (Figure 1B). Isoforms 2 and 3
contain an additional short or long exon, respectively, located
between exons 3 and 4. Despite the fact that most lncRNAs
display only modest sequence conservation due to their rapid
evolution, XLOC_012568 includes a highly conserved region
across mammals (Figures 1B and S1C) (Necsulea et al., 2014).
This conserved region is located within a region of high identity
(54%) to SRA1 (Figures 1B and S1D). While the SRA1 locus
expresses both protein-coding and functional non-coding tran-
scripts, none of the threeSLNCR isoforms exhibit protein-coding
potential (coding potential scores: SLNCR1, 0.12; SLNCR2,
0.10; and SLNCR3, 0.37) (Chooniedass-Kothari et al., 2004;
Kong et al., 2007; Lanz et al., 1999). The conservation of
SLNCR1, its similarity to another functional non-coding RNA,
and its abundant expression across multiple cancers suggest a
functionally important role for SLNCR1.
To annotate SLNCR expression to clinically relevant pa-
rameters, we assessed SLNCR expression across 150 randomly
selected human melanomas from TCGA. It is important to note
that this analysis does not distinguish between SLNCR isoforms.
In agreement with results from patient-derived melanomas,
SLNCR is expressed in 146 out of 150 randomly selected human
melanomas (RPKM [reads per kilobase per million reads] > 1;
Table S1). Tumor depth, as described by Breslow’s thickness
(T, measured in millimeters), is one of the most important
prognostic factors in melanoma treatment. Specifically, while
thin tumors (#1 mm thick) are typically treatable by surgical
excision, thicker tumors (>1 mm thick) have a greater possibility
of reaching blood vessels and are, thus, more likely to metasta-
size, requiring more aggressive treatment. SLNCR expression is
significantly higher in tumors at least 1 mm thick, correlating with
severity of the melanoma (American Joint Committee on Cancer
staging classification TX/Tis/T0/T1 versus T2/T3/T4; Figure 1C).
To investigate whether SLNCR expression is related to dis-
ease outcome in TCGA melanomas, we performed a Kaplan-
Meier survival analysis comparing melanoma patients express-
ing high (n = 72; Figure 1D, red line) or low (n = 70; Figure 1D,
blue line) levels of SLNCR1 defined by the median SLNCR
expression. High expression of SLNCR is associated with
shorter overall survival in melanoma patients (p = 0.0426). The
median survival for the low SLNCR group was 14.3 years, while
the high SLNCR group had a median survival of only 5.3 years.
Additionally, the pooled hazard ratio (HR) shows an 84% in-
crease in the risk of death for the high SLNCR group (log-rank
HR = 1.84, 95% confidence interval = 1.03–3.60). Together,
these data suggest a role for SLNCR at a clinically critical stage
of melanomagenesis.
SLNCR1 Increases Melanoma Invasion by
Transcriptionally Upregulating MMP9
To gain insights into the role of SLNCR in melanoma formation,
we used global transcriptional profiling before and after knock-
down of the most abundant isoform, SLNCR1, in the MSTC
WM1976. Two custom-designed small interfering RNAs (siRNAs)
directed against the exon 3-4 junction resulted in 80%–90%
knockdown of SLNCR1 (Figures 2A and S2A). Due to toxicity
and apparent off-target effects of si-SLNCR1 (2) 48 hr post-trans-
fection, only differentially expressed transcripts from duplicate
knockdown using si-SLNCR1 (1) were used for RNA-seq ana-
lyses (Figure S2B). Knockdown of endogenousSLNCR1 resulted
in the differential expressionof 111 transcripts (adjustedp value<
0.05, fold change > 2; Table S4), indicating that SLNCR1 regu-
lates expression of numerous genes in trans.
Next, we assessedwhetherSLNCR1 promotes cancer pheno-
types in melanoma cells in vitro. First, SLNCR1 expression did
not affect viability or proliferation of melanoma cells, as quanti-
fied using the metabolic reagent WST-1 (Figures S2B and
S2C). Second, SLNCR1 expression did not significantly alter
cell motility, as measured by Transwell migration assays (Fig-
ure S2D). Finally, wemeasured invasion using aMatrigel invasion
assay. SLNCR1 knockdown significantly decreased invasion in
WM1976 (80%) and WM1575 (60%) MSTCs, suggesting
that endogenous SLNCR1 plays a critical role in melanoma inva-
sion (Figures 2B and 2C).
To independently validate a role for SLNCR1 in melanoma
invasion, we overexpressed SLNCR1 in the A375 melanoma
cell line. A375 cells express lower levels of SLNCR1 compared
to patient melanomas (Figure 1A), providing a tractable system
for mechanistic studies of SLNCR1 function. As expected,
overexpression of SLNCR1 increased invasion of A375 cells
(200%; Figures 2D and S2E). Overexpression of a SLNCR1
mutant lacking the highly conserved sequence (SLNCR1Dcons,
nt 462–572 deleted) did not increase invasion, while overexpres-sion of the conserved sequence, including 100 nt of flanking
sequences to ensure proper RNA folding (SLNCR1cons, nt 372–
672), increased invasion to the same degree as full-length
SLNCR1 (200%; Figure 2D). Collectively, these data indicate
that the conserved region is necessary and sufficient for
SLNCR1-mediated melanoma invasion.
To identify genes that mediate increased melanoma invasion,
we overexpressed SLNCR1, SLNCR1Dcons, or SLNCR1cons in
A375 melanoma cells and performed unbiased transcriptional
profiling by RNA-seq. Expression of SLNCR1 resulted in the
differential expression of 110 genes (adjusted p < 0.05, fold
change > 2; Figure S3A; Table S5). Because the conserved
sequence is necessary and sufficient for SLNCR1-mediated
melanoma invasion, we searched for transcripts differentially
expressed upon overexpression of SLNCR1 and SLNCR1cons,
but not SLNCR1Dcons. Using less stringent criteria (p < 0.05, fold
change > 1.5) to ensure identification of all potential candidates,
we identified two transcripts significantly upregulated by
SLNCR1’s conserved sequence: RARRES2P8, a pseudogene of
the retinoic acid receptor responder, andMMP9, a gene that en-
codesmatrixmetallopeptidase9, also knownasgelatinaseB (Fig-
ure 3A). MMP9 contributes to early melanoma invasion through
remodeling of the extracellular matrix (Hofmann et al., 2005;
MacDougall et al., 1995, 1999; van denOord et al., 1997). Consis-
tent with a role in early tumor dissemination, analysis of our TCGA
melanoma cohort revealed thatMMP9 expression is significantly
higher in regional metastases compared to primary tumors
(p = 0.0003; Figure S3B). Furthermore,SLNCR1 expression in pri-
mary melanomas precedes increased MMP9 expression, sup-
porting SLNCR1-regulated expression ofMMP9 (Figure S3B).
Because SLNCR1cons regulates expression of MMP9 and me-
diates SLNCR1-induced invasion, we hypothesized that MMP9
is responsible forSLNCR1-induced invasion. First, we confirmed
that SLNCR1cons is necessary and sufficient for increasing
MMP9 mRNA (2.5-fold), as well as MMP9 enzymatic activity
(50%) (Figures 3B and 3C). Overexpression of lncRNAs, like
proteins, may force non-physiological interactions and subse-
quently cause artifactual downstream effects. To confirm that
endogenous SLNCR1 regulates MMP9, we quantified MMP9
expression and activity in MSTCs following SLNCR1 knock-
down. Consistent with a role in regulating MMP9, SLNCR1
knockdown decreased MMP9 expression (log2 fold change =
0.74; Table S4) in WM1976 and decreased MMP9 activity
(40%–50%) in WM1575 and WM1976 cells (Figures 3D and 3E).
If SLNCR1 increases melanoma invasion by upregulating
MMP9, then depleting MMP9 should block SLNCR1-mediated
invasion. To test this hypothesis, we transfected A375 cells
with empty or SLNCR1-expressing vectors, along with control
or MMP9-specific siRNAs (Figure S3C). As expected, MMP9
knockdown blocked the SLNCR1-mediated increase in MMP9
activity and invasion (Figures S3D–3F). These data demonstrate
that SLNCR1 increases melanoma invasion by upregulating
MMP9.
lncRNAs can transcriptionally or post-transcriptionally regu-
late gene expression. To test whether SLNCR1 transcriptionally
upregulates MMP9, we generated a firefly luciferase (FL) re-
porter under control of the 2-kb MMP9 promoter (MMP9p-FL)
and monitored expression in A375 cells (Figure 3G). WhenCell Reports 15, 2025–2037, May 31, 2016 2027
Figure 2. SLNCR’s Highly Conserved Sequence Increases Melanoma Invasion
(A) Schematic presentation of SLNCR1-specific siRNAs targeting the exon 3-4 junction. Right: relative expression of SLNCR1 upon siRNA knockdown in the
MSTC WM1976. qRT-PCR data are represented as the fold change compared to scramble siRNA control, normalized to GAPDH. Error bars represent SD
calculated from three reactions.
(B and C) Matrigel invasion assays of WM1976 (B) or WM1575 (C) cells transfected with the indicated siRNA. Invasion is calculated as the percent invading cells
compared tomobile cells as counted in eight fields of view. Top panels show representative images of the indicated invading andmobile cells. Quantification from
three independent replicates, represented as mean±SD, is shown at the bottom.
(legend continued on next page)
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Figure 3. SLNCR1 Increases Melanoma Invasion by Transcriptionally Upregulating MMP9
(A) Heatmap of differentially expressed genes significantly regulated by SLNCR1 and SLNCR1cons, but not SLNCR1Dcons, in the melanoma cell line A375. The
shading represents the log2 fold change compared to a vector-only control.
(B) Relative MMP9 expression in A375 cells transfected with the indicated plasmids. qRT-PCR data are represented as the fold change compared to a vector
control, normalized to GAPDH. Error bars represent SD calculated from three reactions.
(C–E) MMP9 activity from supernatants of cells transfected with the indicated plasmids or siRNAs were quantified using gelatin zymography. Percent MMP9
activity is represented as fold change compared to the vector or scramble control, normalized to MMP2 activity. Error bars represent SD from three independent
replicates. (C) Percent MMP9 activity in supernatants of A375 cells transfected with the indicated plasmids. (D) Percent MMP9 activity of WM1976 supernatant
upon knockdown of SLNCR1. (E) Percent MMP9 activity of WM1575 supernatant upon knockdown of SLNCR1.
(F) Matrigel invasion assay of A375 melanoma cells transfected with the indicated plasmids and siRNAs, as in Figures 2B–2D. Error bars represent SD calculated
from three reactions.
(G) A375 cells, grown in steroid-deprived conditions, were transfected with an MMP9p-firefly (FL) reporter plasmid, a CMV-RL (renilla luciferase) control, and the
indicatedSLNCR1 expression plasmids. Luciferase activity wasmeasured 24 hr post-transfection. Relative FL activity was calculated as a fold change compared
to vector only control cells, after normalization to RL activity. Shown is one representative assay from at least three independent replicates. Error bars represent
SD from four reactions.
Significance was calculated using Student’s t test. *p < 0.05; **p < 0.005; ***p < 0.0005; ns, not significant.
See also Figure S3.normalized to expression of renilla luciferase from a co-trans-
fected control reporter plasmid, SLNCR1 expression resulted
in a significant (3.5-fold) increase in FL activity. To further vali-
date the requirement of SLNCR1cons, we generated deletion(D) As in (B) and (C), but with A375 melanoma cells transfected with the indicated
expressed from the indicated plasmids. The bottom left panel shows representat
the right. Significance was calculated using the Student’s t test. Error bars repre
*p < 0.05; **p < 0.005; ***p < 0.0005; ns, not significant.
See also Figure S2.mutants of SLNCR1 and monitored FL activation. In agreement
with previous results showing a requirement of SLNCR1cons,
expression of SLNCR1Dcons did not increase FL activity. Inter-
estingly, deletion of 70 bases immediately 30 to the conservedplasmids. The schematic presentation (top) denotes the SLNCR1 sequences
ive images, while quantification from three independent replicates is shown at
sent SD calculated from three reactions.
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Figure 4. AR and Brn3a Bind to Adjacent SLNCR1 Sequences
(A) Schematic presentation of the RATA method for identifying TFs associated with SLNCR1. SLNCR1-MS2 ribonucleoprotein (RNP) complexes were immu-
noprecipitated with a-FLAG antibody and eluted from beads using FLAG peptide, and the eluate was immediately subjected to the TF Activation Profiling Plate
Array I (Signosis). TF-bound probes were isolated through column separation and analyzed through hybridization with a plate whose wells are pre-coated
with DNA complementary to the probes.
(B) Ectopically expressed FLAG-tagged MS2 was immunoprecipitated from A375 cells transfected with the indicated MS2-loop containing SLNCR1 construct,
compared to control cells expressing untagged SLNCR1 constructs. Left panel: total protein input or bound proteins following IP with a-FLAG antibody was
subjected to western blot analysis. The blot was probed with a-FLAG and a-GAPDH antibodies. Middle and right: relative enrichment of the indicated transcripts
as measured by qRT-PCR compared to RNA enriched from cells expressing SLNCR1without MS2 stem loops. Bound FLAG-MS2 RNPs were eluted using FLAG
peptide.
(C) Fold enrichment of TF-specific probes with MS2-based purification of SLNCR1 or SLNCR1Dcons from A375 cells. Probe enrichment represents fold
enrichment compared to an untagged RNA control IP after normalization to the signal of GATA-specific probes. Shown is one representative assay of TF-specific
probes showing significant (>7-fold) enrichment in at least two out of three replicates.
(legend continued on next page)
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region (SLNCR1D568–637) also failed to increase FL activity, indi-
cating an additional requirement for this sequence in MMP9
regulation. It is important to note that this region is included in
the sequence overexpressed in SLNCR1cons (Figure 2D).
Furthermore, because serum-containing media contain exoge-
nous hormones and steroids that affect activity of steroid
hormone receptors, the assay was performed in the absence
of steroids. SLNCR1 increased FL activity in steroid-deprived
cells, indicating that SLNCR1-mediated regulation of MMP9
is not dependent on exogenous hormones contained in the
media. Collectively, these data confirm that nt 462–637 of
SLNCR1 upregulates the MMP9 promoter in a ligand-indepen-
dent manner.
AR and Brn3a Bind to Adjacent Regions of SLNCR1
Previously characterized lncRNAs ‘‘fine-tune’’ gene expression
through a range of mechanisms (Geisler and Coller, 2013). We
hypothesized that SLNCR1 binds TFs because SLNCR1 (1) is
expressed in the nucleus (Figure S4A), (2) transcriptionally upre-
gulates the MMP9 promoter (Figure 3G), and (3) has sequence
similarity to SRA1 (Figure S1D), which has been shown to bind
to multiple TFs (Colley and Leedman, 2011). Importantly,
TCGA patient melanomas express SLNCR1 at levels compara-
ble to those of SRA1 in other tissues (0–60 RPKM, or approx-
imately up to 100 copies per cell) (http://gdac.broadinstitute.
org) (Harvard, 2015; Kellis et al., 2014; Mortazavi et al., 2008).
Identifying TFs using standard techniques is challenging
because of their low expression. Therefore, we designed a
method for identifying RNA-bound TFs that we term RATA
(RNA-associated transcription factor array). This technique
couples an RNA pull-down with a high-throughput TF activa-
tion array, enabling highly sensitive and unbiased identification
of TFs bound to an RNA of interest (Figure 4A). The bacterio-
phage coat protein MS2 interacts with high affinity to a spe-
cific stem-loop structure in the phage genome and has been
widely adapted for biochemical purification of mammalian
RNAs (Gong and Maquat, 2015). SLNCR1 constructs contain-
ing 12 copies of the MS2 binding sites were co-expressed
with a plasmid expressing nuclear FLAG-tagged MS2 pro-
tein, and immunoprecipitation (IP) with anti-FLAG antibodies
routinely showed 30- to 100-fold enrichment of SLNCR1 or
SLNCR1Dcons (Figure S4B). For subsequent use in the TF acti-
vation array, bound RNAs and proteins were eluted from
beads using FLAG peptide under non-denaturing conditions
(Figure 4B). The eluate was then subjected to a TF Activation
Profiling Plate Array (Signosis), allowing for quantitative anal-
ysis of multiple TFs in a single assay. Pull-downs were(D) IPs fromHEK293T transfected with GFP-tagged AR and the indicated SLNCR1
Top panel: western blot analysis of input (I), IgG-bound (IgG), or a-AR-bound (AR
AR IPs, compared to an IgG nonspecific control. HEK293T cells were transfected
(bottom middle panel) or SLNCR1 D568–637(bottom right panel) expression plasm
(E) IPs from UV-crosslinked HEK293T transfected with Brn3a and the indicate
nonspecific control. Top panel: western blot of input (I), IgG-bound (IgG), or a-Brn
transcripts from Brn3a IPs. HEK293T cells were transfectedwith Brn3a and either
differences in the efficiency of proteinase K digestion, enrichment was calculated c
All qRT-PCR data are represented as mean±SD from three replicates.
See also Figure S4.repeated in triplicate, and TFs showing specific >7-fold enrich-
ment compared to the untagged control in at least two exper-
iments were considered potential candidates.
To identify TFs binding to the conserved region of SLNCR1, we
compared probes enriched from SLNCR1 versus SLNCR1Dcons
IPs. Probes for Brn3a (Pou4F1) routinely showed strong enrich-
ment with SLNCR1 but showed negligible enrichment upon dele-
tion of the conserved sequence, suggesting that Brn3a binds to
the conserved region. Although Brn3a has not previously been
shown to bind RNA, the TF contains a predicted RNA-binding
motif in amino acid position 143–175 (MOTIF Search; http://
www.genome.jp/tools/motif/). Importantly, Brn3a has been impli-
cated in melanoma cell-cycle progression (Hohenauer et al.,
2013).
We also observed modest enrichment of probes specific for
AR, EGR1, E2F-1, ATF2, and AP2. Of these, we focused on AR
for several reasons: (1) AP2, ATF2, E2F-1, and EGR1 directly
or indirectly interact with AR (Altintas et al., 2012; Jorgensen
and Nilson, 2001; Verger et al., 2001; Zhang et al., 2010), sug-
gesting that enrichment of these probes is a consequence of
protein-protein interactions rather than direct interaction with
SLNCR1. (2) Transcriptional network analysis of melanomas
overexpressing or knocking down SLNCR1 reveals significant
enrichment of AR-regulated genes (Table S4: SLNCR1 knock-
down, p = 1.45e59, Z score = 134.17; Table S5: SLNCR1 over-
expression, p = 5.070E63, Z score = 160.15; MetaCore, Thom-
son Reuters). (3) AR directly binds to other lncRNAs (Yang et al.,
2013; Zhang et al., 2015). (4) AR positively regulates MMP9 in
other cancers, including gastric, bladder, and prostate cancers
(Erg€un et al., 2007; Hara et al., 2008; Wang et al., 2013; Wu
et al., 2010; Zhang et al., 2014). Notably, (5) melanomas express
AR (Allil et al., 2008; Morvillo et al., 2002).
To validate SLNCR1cons binding to AR and Brn3a, we per-
formed RNA IP (RIP) assays in HEK293T cells, which express
very low levels of endogenous SLNCR1. SLNCR1 is significantly
enriched (120-fold) in RNAs immunoprecipitating with ectopi-
cally expressed AR (Figure 4D). Surprisingly, SLNCR1Dcons is still
enriched in AR immunoprecipitates (50-fold). RNA secondary
structure is often critical to RNA function; thus, deletion of the
conserved sequencemay disrupt adjacent secondary structures
and weaken the interaction of AR and SLNCR1 in the RATA
assay. We note that SLNCR1568–637 is required for MMP9 upre-
gulation (Figure 3G), suggesting that AR binds to this region adja-
cent to the conserved region. Consistent with this hypothesis,
SLNCR1D568–637 is not enriched above background levels of
endogenous SLNCR1 (Figure 4D; data not shown). Taken
together, these data confirm that AR binds to SLNCR1568–637.expressing plasmids using either a-AR antibody or an IgG nonspecific control.
) proteins. Bottom panels: relative enrichment of the indicated transcripts from
with GFP-tagged AR and either SLNCR1 (bottom left panel) or SLNCR1 Dcons
ids.
d SLNCR1 expression plasmid using either anti-Brn3a antibody or an IgG
3a-bound (Brn3a) proteins. Bottom panels: relative enrichment of the indicated
SLNCR1 (bottom left panel) orSLNCR1 Dcons (bottom right panel). To control for
ompared to input transcript levels after normalization to levels of the 18S rRNA.
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Figure 5. SLNCR1-Mediated Invasion Requires AR and Brn3a
(A–F) In (A) and (D), MMP9 activity is shown for A375 cells transfected with the
indicated plasmids and siRNAs, as in Figures 3C–3E. (B and E) Relative
luciferase activity of A375 cells transfected with an MMP9-RL reporter, as well
as the indicated plasmids and siRNAs. Quantification was performed as in
Figure 3G. (C and F) Matrigel invasion assay of A375 melanoma cells
transfected with the indicated plasmids and siRNAs. The top panel shows
representative images of the indicated invading or mobile cells, and the
quantification from three independent replicates is shown at the bottom.
Significance was calculated using the Student’s t test: *p < 0.05; n.s., not
significant.
Error bars in (A), (C), (D), and (F) represent SD calculated from three reactions.
Error bars in (B) and (E) represent SD calculated from four reactions. See also
Figure S5.
2032 Cell Reports 15, 2025–2037, May 31, 2016To capture specific Brn3a-RNA interactions, we used UV light
to crosslink HEK293T cells prior to IP of Brn3a. SLNCR1 is signif-
icantly enriched in Brn3a immunoprecipitates (1,500-fold),
while SLNCR1Dcons shows no enrichment (Figure 4E), confirming
that Brn3a binds directly to SLNCR1462–572.
Upregulation ofMMP9 Requires SLNCR1, AR, and Brn3a
Because Brn3a binds to SLNCR1’s conserved region and AR
binds to an adjacent sequence, respectively, we hypothesized
that all three components are required for upregulation of
MMP9 and melanoma invasion. If SLNCR1 coordinates tran-
scriptional activity of both TFs, MMP9 should not significantly
contribute to melanoma invasion in the absence of any single
component. It is important to note that, in A375 cells, SLNCR1
is required for MMP9-mediated invasion, because knockdown
of MMP9 does not decrease invasion of low-SLNCR1-express-
ing A375 cells (Figure 3F, vector-only samples). To confirm a
specific requirement for AR and Brn3a, we repeated gelatin
zymography, MMP9p-FL reporter, and Matrigel invasion assays
after overexpressing SLNCR1 and simultaneously knocking
down either of the TFs in the A375melanoma cell line. Consistent
with our hypothesis that AR is required for regulating MMP9
activity, depleting AR prevented MMP9 activation and promoter
upregulation, as well as melanoma invasion, after SLNCR1 over-
expression (Figures 5A–5C and S5A–S5D). This confirms that AR
is required for SLNCR1-mediated invasion, even when both
Brn3a and SLNCR1 are present (Figure 5C).
To test whether Brn3a is also required for SLNCR1-mediated
invasion, we repeated the aforementioned assays using Brn3a-
specific siRNAs. Similar to results seen with AR, depleting
Brn3a prevented SLNCR1-mediated upregulation of MMP9
activity and promoter upregulation (Figures 5D, 5E, and S5E–
S5G). We also performed invasion assays of A375 melanoma
cells expressing vector alone or SLNCR1 in the presence of
scramble or Brn3a-specific siRNAs (Figure 5F). Interestingly,
knockdown of Brn3a increased melanoma invasion. However,
this increased invasion occurred independently of an increase
in MMP9 (Figures 5D and 5E). Most importantly, expressing
SLNCR1 does not increase melanoma invasion when Brn3a
is depleted (Figure 5F; compare bar 3 to bar 4 and bar 5 to
bar 6). Thus, our data indicate that Brn3a regulatesmelanoma in-
vasion through two pathways: one independent of SLNCR1 and
MMP9 and another that requires AR and SLNCR1 to upregulate
MMP9. Because knockdown of AR or Brn3a completely abro-
gates upregulation of MMP9 and SLNCR1-mediated melanoma
invasion, our data demonstrate a functional requirement for
SLNCR1, AR, and Brn3a and suggests formation of a ternary
complex composed of SLNCR1, AR, and Brn3a.
SLNCR1 Increases AR Binding to theMMP9 Promoter
lncRNAs may direct TFs to target regions in the chromosome
through direct binding to DNA and formation of an RNA-DNA
complex or by acting as scaffolds to assemble a complex of
multiple TFs and regulatory proteins (Geisler and Coller, 2013;
Wang and Chang, 2011). We observe no significant similarity be-
tween SLNCR1 and the MMP9 promoter, arguing against a
direct interaction between SLNCR1 and the DNA. Supporting a
model of direct TF binding to MMP9 promoter elements, the
Figure 6. AR and Brn3a Binding Sites Are Required for SLNCR1-
Induced Upregulation of the MMP9 Promoter
(A) Schematic presentation of the 2 KB MMP9 promoter cloned upstream of
the firefly luciferase reporter. The black box denotes a predicted Brn3a binding
site. The wild-type and mutated sequences are shown below. The black circle
denotes a functional ARE, with wild-type and mutated sequences below. The
gray circles denote additional predicted AREs.
(B) Mutation of either the Brn3a binding site (MMP9p-FL BBS mut) or the ARE
(MMP9p-FL ARE mut) prevents SLNCR1-mediated upregulation of the MMP9
promoter. Assay was completed as in Figure 3G. Error bars represent SD from
four reactions.
(C) AR ChIP from A375 cells transfected with either vector or SLNCR1-ex-
pressing plasmid. qPCR was performed using primers specific to the regions
indicated, including primers corresponding to a gene desert (negative control).
Error bars represent SD calculated from three reactions.
*p < 0.05; **p < 0.005; n.s., not significant.
See also Figure S6.MMP9 promoter contains multiple functional AREs (androgen
response elements), as well as a nearly perfect consensus
Brn3a binding site (gcAT[A/T]A[T/A]T[A/T]AT) (Figure 6A) (Gruber
et al., 1997; Zhang et al., 2014). To test whether these TF binding
sites (TFBSs) are required for SLNCR1-mediated transcriptional
upregulation of MMP9, we generated MMP9p-FL reporter con-
structs harboring mutations within the predicted ARE (MMP9p-
FL ARE mut) or the Brn3a binding site (MMP9p-FL BBS mut).While overexpression of SLNCR1 in A375 cells significantly
increased luciferase expression from the wild-type MMP9p-FL
reporter, mutation of either the predicted Brn3a binding site or
the ARE abolished the ability of SLNCR1 to increase luciferase
activity (Figure 6B). These data further suggest formation of a
ternary complex composed of SLNCR1, AR, and Brn3a at the
MMP9 promoter.
Next, we used chromatin IP (ChIP) and PCR (ChIP-PCR) to test
whether AR directly binds to theMMP9 promoter. Compared to
a vector-only control, AR is significantly enriched (2-fold) at the
MMP9 promoter in the presence of SLNCR1 (Figure 6C). Collec-
tively, these data indicate that binding of AR, and likely Brn3a, to
the MMP9 promoter is required for transcriptional activation of
MMP9.
Finally, we examined our TCGA melanoma cohort for in vivo
evidence of AR-mediated regulation of MMP9. Expression of
AR and MMP9 are significantly correlated (r = 0.41, p = 0.0003)
in high-SLNCR melanomas (RPKM P 14.1), but not in low-
SLNCR1 melanomas (RPKM < 14.1), suggesting that AR is
bound to the MMP9 promoter only when SLNCR1 expression
reaches a certain threshold (Figure S6). These data are consis-
tent with AR- and SLNCR1-mediated regulation of MMP9 in
patient melanomas.
DISCUSSION
lncRNAs are emerging as important players in cancer biology;
however, the mechanistic details of most lncRNA functions
remain unknown. Here, we identify SLNCR as a robustly ex-
pressed lncRNA associated with worse overall melanoma sur-
vival. SLNCR1 increases melanoma invasion by transcriptionally
upregulating MMP9. Our work provides direct biochemical evi-
dence that SLNCR1 physically interacts with both AR and
Brn3a and that all three components are required for upregulat-
ing MMP9. The Brn3a and AR binding sites are located approx-
imately 100 nt apart, an orientation consistent with cooperative
TF binding. Our data, therefore, supports a model in which
SLNCR1 mediates formation of a nuclear SLNCR1/AR/Brn3a
ternary complex with high affinity for the proximal TFBSs in the
MMP9 promoter (Figure 7). Taken together, this study identifies
SLNCR1 as an oncogenic lncRNA with a critical role in melano-
magenesis. This finding is in agreement with a recent report in
which linc00673 (SLNCR1) was identified as a possible onco-
gene in non-small-cell lung cancer (Shi et al., 2016).
Although canonical AR activation occurs upon the binding of
an androgenic hormone ligand, translocation to the nucleus,
and AR dimerization, our data aremost consistent with ligand-in-
dependent activation of AR and formation of an AR/Brn3a heter-
odimer. First, SLNCR1 upregulates the MMP9 promoter in the
absence of exogenous steroids (Figure 3G) or increased nuclear
localization of AR (Figure S7A), consistent with ligand-indepen-
dent activation of AR. Second, if SLNCR1 induced canonical
AR dimerization, overexpression of the lncRNA would increase
the global activity of AR as opposed to only a subset of AR-target
genes (Table S5). Third, other AR-associated lncRNAs have
been shown to induce AR in a ligand-independent manner
(Yang et al., 2013; Zhang et al., 2015). Fourth, AR forms func-
tional heterodimers with other TFs and was previously shownCell Reports 15, 2025–2037, May 31, 2016 2033
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Figure 7. Model for SLNCR1-Induced MMP9 Transcriptional
Upregulation
When SLNCR1 increases, AR and Brn3a bind to conserved, adjacent regions
of SLNCR1. The SLNCR1/AR/Brn3a ternary complex has high affinity for
adjacent Brn3a and AR binding sites located upstream of the MMP9 tran-
scriptional start site. Cooperative binding of AR and Brn3a to its promoter
increases MMP9 expression and activity and thus increases invasion of
melanoma cells.
See also Figure S7.to directly bind Brn3a in mouse ND7 cells (Berwick et al., 2010;
Chen et al., 1997; Lee et al., 1999). These data are consistent
with the formation of a heterodimer TF complex, which increases
TF affinity for the tandem TFBSsmore significantly than either TF
alone. An AR monomer has only low affinity for AREs. Similarly,
Brn3a has lower affinity for non-consensus TFBSs, such as the
one located upstream of MMP9 (Gruber et al., 1997). Formation
of an AR/Brn3a heterodimer likely allows for cooperative binding
of the TFs to their respective TFBSs, effectively concentrating
the nuclear AR in melanoma cells to specific promoters,
including the MMP9 promoter.
It is verydifficult to predict lncRNA function basedon sequence
analysis, because lncRNAs are not as conserved as protein-
codinggenes (Necsulea et al., 2014).However,SLNCR1contains
a region highly conserved among mammals that is also similar
to a region of SRA1, allowing us to extrapolate the function of
SLNCR1cons from a wide range of possibilities. In addition to
SRA1, the lncRNA HOTAIR and, possibly, the lncRNAs PRNCR1
and PCGEM1 bind to AR (Agoulnik and Weigel, 2009; Prensner
et al., 2014; Yang et al., 2013; Zhang et al., 2015). We note a
significant sequence similarity between regions of PCGEM1,
HOTAIR, SLNCR1, and SRA1 (Figure S7B), suggesting that it is
feasible to predict lncRNA function from these sequences. Iden-
tification of functional lncRNA sequencesmay enable determina-
tion of the mechanisms of uncharacterized lncRNAs.2034 Cell Reports 15, 2025–2037, May 31, 2016Whereas this work has focused on a region of SLNCR1 with
sequence and functional similarities to SRA1, there are several
important differences between the lncRNAs. (1) SRA1 has not
been implicated in melanoma and is not differentially expressed
between normal melanocytes and melanomas (data not shown).
(2) While SRA1 binds to multiple steroid receptors, including AR,
there is no evidence that it interacts with Brn3a or regulates
MMP9 (Lanz et al., 1999). (3) Most importantly, siRNA-mediated
knockdown of SLNCR1 does not affect levels of SRA1 (Fig-
ure S2A), indicating that the decrease in invasion (Figures 2B
and 2D) and differential gene expression patterns (Table S4)
are attributable to the depletion of SLNCR1 and not SRA1.
SLNCR1, therefore, functions independently of SRA1 to regulate
melanoma invasion. Identification and analysis of additional
functional regions ofSLNCR1 outside of theSRA1-like sequence
will be an important topic for future studies. For example,
SLNCR1cons is required for only a small fraction of SLNCR1’s
gene-regulatory function (Figure S3A). A candidate SLNCR1-in-
teracting TF binding outside of its conserved sequence is PAX5,
a TF involved in B cell differentiation (Figure 4C). In addition to
TF-dependent functions, SLNCR1 may have TF-independent
functions, such as through interactions with mRNAs, micro-
RNAs, or splicing factors, some of which may occur in the cyto-
plasm (Figure S4A) (Geisler and Coller, 2013).
A gender bias in melanoma biology favoring females was
first considered over 40 years ago (Clark et al., 1969). In the years
since this study, other studies have confirmed that females have
a significant survival advantage compared tomales (38%), fewer
and delayedmetastases, longer delay before relapse, and higher
cure rates than males, strongly suggesting a biological basis for
the observed gender bias (Bidoli et al., 2012; de Vries et al., 2007;
Fisher and Geller, 2013; Gamba et al., 2013; Geller et al., 2002;
Joosse et al., 2011, 2012; Schwartz et al., 2002; Swetter et al.,
2009). Differences in expression or activity of sex-hormone re-
ceptors, including the estrogen receptor or AR, have long been
considered a plausible explanation for the melanoma gender
bias (de Giorgi et al., 2011; Morvillo et al., 2002). Recent studies
favor a deleterious role for AR and androgens inmelanoma, as (1)
the female advantage persists even in post-menopausal women,
suggesting against an estrogen-related advantage (de Vries
et al., 2008; Joosse et al., 2011; Micheli et al., 2009), and (2) there
is an increased risk of melanoma following prostate cancer, and
vice versa, suggesting an AR-based connection between the
two cancers (Li et al., 2013b; Spanogle et al., 2010). Our results
directly implicate AR in melanoma invasion by interacting with
SLNCR1 and upregulating MMP9, possibly reconciling the
observation that males suffer an increased number of melanoma
metastases.EXPERIMENTAL PROCEDURES
Cell Culture
Primary human melanocytes were derived from neonatal foreskins and
cultured as previously described (Yokoyama et al., 2008). All other cells
were cultured as adherent cells in DMEM (Invitrogen) without glutamine sup-
plemented with 10% fetal bovine serum (FBS). A375 cells were purchased
from the ATCC, HEK293T cells were a gift fromRonny Drapkin, CYmelanomas
were derived by C.H.Y., and WM melanomas were from collections of the
Wistar Institute.
For luciferase assays, cells were cultured in phenol-red-free DMEM without
glutamine (Invitrogen), supplemented with 5% charcoal-stripped FBS. Lucif-
erase activity was measured using the Promega Dual-Glo Luciferase Assay
system. For fractionation experiments, cells were grown to 80% confluency
in 10-cm tissue-culture-treated dishes and fractionated using the Thermo
Scientific NE-PER Nuclear and Cytoplasmic Extraction Kit, according to the
manufacturer’s instructions. Nuclear and cytoplasmic fractions were split for
protein and RNA analysis. For proliferation assays, cells were transfected
with the indicated siRNAs 24 hr post-seeding, and proliferation was measured
every 24 hr using WST-1 reagent (Roche) according to the manufacturer’s in-
structions. For ChIP-PCR, A375 cells were cultured in phenol-red-free DMEM
without glutamine (Invitrogen), supplemented with 5% charcoal-stripped FBS,
and transfected with the indicated plasmid 24 hr post-seeding. Cells were
crosslinked in 1% formaldehyde for 15 min 48 hr post-transfection, and the
reaction was quenched by addition of 0.125 M glycine. ChIP and PCR were
performed by Active Motif. The FKBP5 control primers amplified a region
roughly +87,015 to the gene, and MMP9 specific primers amplified a region
2,254 to the gene.
Invasion Assays
Cells were plated in either BD BioCoat Matrigel inserts or uncoated control in-
serts (Corning) in serum-freemedia and placed into DMEMwith 30%FBS. The
number of invaded or migrant cells were imaged at 203magnification in eight
fields of view for three independent replicates.
Plasmid Construction
SLNCR1 and a codon-optimized Brn3a were synthesized by Biomatik and
cloned into pCDNA3.1 (). The simian virus 40 nuclear localization signal
(SV40-NLS) was cloned upstream of the MS2 open reading frame (ORF) in a
FLAG-tagged, hMS2-expressing vector, a gift from Dr. Lynne Maquat, Univer-
sity of Rochester Medical Center. Nuclear localization of tagged MS2 was
confirmed via fractionation and western blotting. pEGFP-C1-AR was a gift
from Michael Mancini (Addgene plasmid #28235).
Reagents and Antibodies
Lipofectamine RNAiMax (Life Technologies) was used for all siRNA trans-
fections, and Lipofectamine 2000 (Life Technologies) was used for all plasmid
transfections and siRNA/plasmid co-transfections. Protein G Dynabeads
(Life Technologies) were used for FLAG-MS2 IPs, and Protein A Dynabeads
(Life Technologies) were used for AR and Brn3a IPs. The following antibodies
were used: (Sigma) Monoclonal ANTI-FLAG M2 antibody; (Santa Cruz
Biotechnology) AR (N-20), Brn3a (14A6), Hsp90 (4F10), and rabbit IgG (immu-
noglobulin G) control; (Cell Signaling Technology) GAPDH (14C10); (Abcam)
SNRNP70 (ab83306); and (BD Pharmingen) mouse IgG control. Santa Cruz
AR (H-280) was used for ChIP-PCR. Sequences for all siRNAs and oligos
used in this study can be found in Table S6.
RNA Pull-Downs
A375 cells were grown to 80% confluency in 10-cm dishes, transfected with
10 mg of the plasmid encoding nuclear MS2 and 8 mg of the indicated 30 MS2
stem-loop-tagged SLNCR1, and harvested 36–48 hr post-transfection. MS2-
tagged SLNCR1 was confirmed functional by qRT-PCR of selected SLNCR1
transcriptional targets (data not shown). MS2RNApull-downswere completed
from non-crosslinked cells using a slightly modified protocol from Gong and
Maquat, (2015). For samples immediately subjected to western blot analysis,
beads were resuspended in 25 ml 23 Laemmli sample buffer and incubated
at 95C for 5 min. For pull-down extracts subjected to TF array analysis, 25 ml
of wash buffer containing flag peptide at a final concentration of 0.1 mg/ml
was added, and beads were rotated for 30min at 4C. 12 ml of eluate was incu-
bated with biotinylated DNA probe mixture from the Signosis TF Activation
ProfilingPlateArray I andsubjected todownstreamanalysis, according toman-
ufacturer’s instructions. The signal corresponding to each TF was normalized
to that of GATA and represented as a fold enrichment compared to a cell trans-
fected with a plasmid encoding SLNCR1 without the MS2 stem-loop tag.
RIP assays were performed using HEK293T cells co-transfected with
pEGFP-C1-AR or pCDNA-Brn3a and the indicated SLNCR1-expressing
plasmids.RNA Extraction and cDNA Library Preparation
RNA was isolated using TRIzol (Life Technologies) and the QIAGEN RNeasy
Mini Kit and treated with DNase. cDNA was generated using SuperScript III
(Invitrogen) reverse transcriptase. The indicated transcripts were quantified
using Platinum SYBR Green qPCR SuperMix-UDG mix on a CFX384 Touch
Real-Time PCR Detection System.
The t test statistics, Pearson correlations, HR, and Kaplan-Meier survival
analysis were performed using GraphPad Prism, version 6.00 for Windows
(GraphPad software). Image quantifications were performed using ImageJ
software.
Please see the Supplemental Experimental Procedures for complete
information.
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